Join our community of smart investors

Hikma lifts guidance on generics division revenue surge

The FTSE 100 company expects generics' revenues to reach a higher range than previously forecast
August 6, 2021

 

  • Generics sales rose a third to $400m in the six months ending June
  • The generics unit launched four products in the first half

A strong first half for Hikma Pharmaceuticals (HIK) has prompted the FTSE 100 company to raise its full-year guidance, even as it lapped a particularly strong start to 2021.

This is subscriber only content
Start your trial to keep reading
PRINT AND DIGITAL trial

Get 12 weeks for £12
  • Essential access to the website and app
  • Magazine delivered every week
  • Investment ideas, tools and analysis
Have an account? Sign in